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Abstract
Introduction: Deregulation of cadherin expression, in particular the loss of epithelial (E)-cadherin and gain of
neural (N)-cadherin, has been implicated in carcinoma progression. We previously showed that endothelial cell-
specific vascular endothelial (VE)-cadherin can be expressed aberrantly on tumor cells both in human breast cancer
and in experimental mouse mammary carcinoma. Functional analyses revealed that VE-cadherin promotes tumor
cell proliferation and invasion by stimulating transforming growth factor (TGF)-b signaling. Here, we investigate the
functional interplay between N-cadherin and VE-cadherin in breast cancer.
Methods: The expression of N-cadherin and VE-cadherin was evaluated by immunohistochemistry in a tissue
microarray with 84 invasive human breast carcinomas. VE-cadherin and N-cadherin expression in mouse mammary
carcinoma cells was manipulated by RNA interference or overexpression, and cells were then analyzed by
immunofluorescence, reverse transcriptase-polymerase chain reaction, and western blot. Experimental tumors were
generated by transplantation of the modified mouse mammary carcinoma cells into immunocompetent mice.
Tumor growth was monitored, and tumor tissue was subjected to histological analysis.
Results: VE-cadherin and N-cadherin were largely co-expressed in invasive human breast cancers. Silencing of N-
cadherin in mouse mammary carcinoma cells led to decreased VE-cadherin expression and induced changes indicative
of mesenchymal-epithelial transition, as indicated by re-induction of E-cadherin, localization of b-catenin at the cell
membrane, decreased expression of vimentin and SIP1, and gain of epithelial morphology. Suppression of N-cadherin
expression also inhibited tumor growth in vivo, even when VE-cadherin expression was forced.
Conclusions: Our results highlight the critical role of N-cadherin in breast cancer progression and show that
N-cadherin is involved in maintaining the malignant tumor cell phenotype. The presence of N-cadherin prevents the
re-expression of E-cadherin and localization of b-catenin at the plasma membrane of mesenchymal mammary
carcinoma cells. N-cadherin is also required to maintain the expression of VE-cadherin in malignant tumor cells but not
vice versa. Thus, N-cadherin acts in concert with VE-cadherin to promote tumor growth.
Introduction
Cadherins are a family of transmembrane proteins that,
together with their associated intracellular catenins,
have important functions in cell-cell adhesion. Different
cell types express different members of the cadherin
family. Epithelial (E)-cadherin is a key component of
adherens junctions in epithelial cells and functions as a
suppressor of tumor growth and invasion. Perturbation
of its function leads to an invasive phenotype in many
tumors [1-3]. Neural (N)-cadherin is expressed in neural
tissues and fibroblasts, where it mediates a less stable
and more dynamic form of cell-cell adhesion [1-4]. Vas-
cular endothelial (VE)-cadherin is the primary compo-
nent of endothelial cell adherens junctions and has an
important function in regulating vascular permeability
and angiogenesis [5]. Because of the important role
played by cadherins in cell recognition, adhesion, and
signaling, modulation of their function and expression
has significant implications for the progression of
tumors [1,6-10]. For instance, a switch from E-cadherin
to N-cadherin expression contributes to increased
tumor cell migration, invasion and metastasis [8-10].
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Aberrant expression of VE-cadherin was first detected in
aggressive melanoma cells and in some cases of sarcoma
[11-13]. A recent study from our group has revealed
that VE-cadherin is expressed aberrantly in a subset of
tumor cells in human breast cancer [7]. In a mouse
mammary carcinoma model, VE-cadherin expression
was induced in cancer cells that had undergone epithe-
lial-mesenchymal transition (EMT). Functional experi-
ments showed that VE-cadherin promotes malignant
tumor cell proliferation and invasion by enhancing the
protumorigenic transforming growth factor-beta (TGF-
b) pathway. However, the functional interaction between
VE-cadherin and N-cadherin during tumor progression
is poorly characterized to date.
EMT was first described by Elizabeth Hay in the 1980s
as a central process in early embryonic morphogenesis
[14]. The initial step of EMT includes the loss of epithe-
lial markers such as E-cadherin via its transcriptional
repression and the gain of mesenchymal markers such
as vimentin. As a consequence, the cadherin-binding
partner b-catenin can dissociate from the E-cadherin
complex at the plasma membrane and translocate to the
nucleus where it participates in EMT signaling and acti-
vates genes involved in tumor progression [15]. Epithe-
lial cells then lose their typical baso-apical polarization
as cell-cell junctions disassemble. Additionally, the
cytoskeleton undergoes dynamic cortical actin remodel-
ing and gains the front-rear polarization that facilitates
cell movement [16]. Finally, cell-matrix adhesion
changes as proteolytic enzymes such as matrix metallo-
proteases are activated [17,18]. The transition from an
epithelial to mesenchymal phenotype is reversible; for
example, several rounds of EMT and mesenchymal-
epithelial transition (MET) occur during development as
cells differentiate and the complex three dimensional
structure of internal organs forms [19]. There is increas-
ing evidence that EMT also facilitates the dissemination
of tumor cells to form distant metastasis [20]. Various
publications have described a switch between the epithe-
lial and mesenchymal phenotypes through EMT and
MET in models of colorectal [21], bladder [22], ovarian
[23] and breast cancer [24]. These findings indicate that
the phenotypic conversion of tumor cells in the meta-
static cascade is multifaceted, with EMT being critical
for the initial transformation from benign to invasive
carcinoma and the spreading of tumor cells, but MET
occurring at the site of metastatic colonization [6].
The mouse mammary carcinoma model that we have
previously used to study the expression of cadherins [7]
utilizes tumor cell lines that represent different stages of
tumor progression: Ep5 cells are tumorigenic mammary
epithelial cells transformed by the v-Ha-Ras oncogene,
whereas Ep5ExTu cells, isolated from Ep5 cell tumors
grown in mice, have undergone EMT in vivo and
present a mesenchymal, invasive and angiogenic pheno-
type [25,26]. We observed that VE-cadherin expression
is induced in these murine breast cancer cells during
(TGF-b-mediated) EMT [7]. On the other hand, E-cad-
herin expression was downregulated, and N-cadherin
levels remained unchanged. Silencing VE-cadherin
expression inhibited tumor cell proliferation and inva-
sion in vitro, and experimental tumor growth in mice.
However, the role of N-cadherin and its potential inter-
action with VE-cadherin in this model is unclear. Here,
we investigate the influence of N-cadherin on EMT and
tumor progression in Ep5ExTu cells. Silencing N-cad-
herin significantly decreased VE-cadherin expression
and stimulated Ep5ExTu cells to re-express E-cadherin
at the cell surface. This promoted localization of b-cate-
nin at the plasma membrane and induced the cells to
undergo MET. Efficient silencing of N-cadherin expres-
sion in Ep5ExTu cells consistently inhibited tumor
growth, and complete tumor regression was even seen
in some cases. Taken together, these results reveal a




Ep5 and Ep5ExTu cells were cultured as described [26] in
Dulbecco’s modified Eagle’s medium (DMEM-F12; Lonza,
Basel, Switzerland) supplemented with 15% fetal calf serum
(FCS). 293T cells were kept in DMEM Glutamax (Gibco,
Darmstadt, Germany) supplemented with 10% FCS.
Generation of VE-cadherin or N-cadherin-silenced
Ep5ExTu cells
Oligonucleotides (Eurogentec, Seraing, Belgium) encod-
ing small interfering RNA (siRNA) molecules specific for
mouse VE-cadherin (5’-GUCUCUGAGU ACUUCCU
UA-3’) or N-cadherin (5’-GGAUGUGCAG GAAGGACA
G-3’ and 5’-UGUCAAUGGG GUUCUCCAC-3’) were
designed and verified to be specific for each cadherin by
a Blast search (National Center for Biotechnology Infor-
mation, Bethesda, MD, USA) against the mouse genome.
A scrambled oligonucleotide sequence without significant
homology to murine sequences (5’-AGUCGCUUAG
AAACGAGAA-3’) was used as a control. These oligonu-
cleotides were then cloned into the lentiviral vector,
pLVTHM, according to the guidelines provided by Tro-
nolab (Laboratory of Virology and Genetics, École Poly-
technique Fédérale de Lausanne, Switzerland). Viral
particles were produced by transient co-transfection of
293T cells with the recombinant pLVTHM lentivector
constructs, the packaging vector psPAX2 and the envel-
ope vector pMD2.G. Ep5ExTu cells were then transduced
with the lentiviral particles contained in supernatants of
transfected 293T cells, and stable cell lines were selected
Rezaei et al. Breast Cancer Research 2012, 14:R154
http://breast-cancer-research.com/content/14/6/R154
Page 2 of 15
by fluorescence-activated cell sorting (FACS) on the basis
of green fluorescent protein (GFP) expression. Clones
of Ep5ExTu cells expressing Sh-VE-cadherin and Sh-N-
cadherin were expanded and the expression of VE-cad-
herin and N-cadherin was monitored by immunoblot.
Experiments were approved by the Sächsisches Staatsmi-
nisterium für Umwelt und Landwirtschaft, Dresden,
Germany (Re: 55-8811.72/69).
Silencing VE-cadherin or N-cadherin in human breast
cancer cell lines
Human SUM 149 cells were cultured in DMEM-F12 sup-
plemented with 15% FCS. Silencing of human N-cadherin
or human VE-cadherin was performed by using SMART-
pools (Dharmacon, Lafayette, CO, USA). Cells (1-2 × 105)
were seeded in 2 ml DMEM, 15% FCS in 6-well plates
24 h before transfection. The medium was replaced by
2 ml Opti-MEM I (Invitrogen, Karlsruhe, Germany) 1 h
before transfection. 100 pmol siRNA was mixed with 500
μl Lipofectamine 2000 (Invitrogen) diluted in a final
volume of 1 ml Opti-MEM I and incubated for 30 min at
room temperature to allow the formation of complexes.
For transfection, the medium was removed and the DNA-
Lipofectamine mixture was added to the cells, which were
then incubated at 37°C. 1 ml DMEM, 15% FCS was added
6 h after transfection and the cells were cultivated for
another 24 h before analysis.
Generation of Sh-N-cadherin cell lines stably expressing
VE-cadherin
Mouse cDNA encoding VE-cadherin (kindly provided by
Prof. D. Vestweber, Münster, Germany) was cloned into
the P6NST50 vector (kindly provided by Prof. D. Linde-
mann, Dresden, Germany). Ep5ExTu (Sh-N-cad2) cells
were transduced with the VE-cadherin-encoding virus
particles. Cells stably expressing VE-cadherin were then
selected by FACS on the basis of their GFP expression.
Cell proliferation
Ep5ExTu cells (105) were plated and labeled with bromo-
deoxyuridine (BrdU) in 96-well plates in DMEM-F12
supplemented with 15% FCS. After 24 h, cell proliferation
was quantified using a colorimetric immunoassay based
on BrdU incorporation according to manufacturer’s
instructions (Roche, Mannheim, Germany). The amount
of BrdU incorporated into the cells was measured by
using an ELISA plate reader (Plus MS2 Reader, Titertek,
Huntsville, AL, USA). For each independent experiment,
six wells per condition were used.
RNA isolation and reverse transcription-PCR analysis
Ep5ExTu cells (2 × 105) were seeded in 4 ml DMEM-F12
supplemented with 15% FCS in 6 cm dishes 24 h before
RNA isolation. Total RNA was isolated from cell lysates
using a universal RNA Purification Kit according to the
manufacturer’s protocol (Roboklon, Berlin, Germany).
Aliquots of 3 μg of total RNA were reverse transcribed
using Superscript II (Invitrogen, Karlsruhe, Germany)
and random hexameric primers (Roche, Mannheim,
Germany). The sequences of the PCR primers used are
shown in Additional file 1. The intensity of the PCR
bands was quantified using Bio-Rad densitometer and
Quantity One analysis software (Hercules, CA, USA).
qRT-PCR analysis for human VE-cadherin and N-cad-
herin was performed following reverse transcription of
total RNA using a Reverse Transcriptase Core Kit (Euro-
gentec, Seraing, Belgium), by real-time PCR (Mastercy-
cler ep Realplex; Eppendorf, Hamburg, Germany) using
QuantiFast SYBR Green PCR Kit (Qiagen, Valencia, CA,
USA). All reactions were run in duplicates and Ct values
were normalized against the GAPDH gene, using the
delta-delta-Ct method. Primer sequences used were: VE-
cadherin (CDH5), (forward) 5’-CGT GAG CAT CCA
GGC AGT GGT AGC-3’, (reverse) 5’-GAG CCG CCG
CCG CAG GAA G-3’; N-cadherin (CDH2) (forward) 5’-
CCA CCT TAA AAT CTG CAG GC-3’, (reverse) 5’-
GTG CAT GAA GGA CAG CCT CT-3’; GAPDH, (for-
ward) 5’-CTC CTC TGA CTT CAA CAG CGA CA-3’,
(reverse) 5’-GAG GGT CTC TCT CTT CCT CTT GT-3’.
Immunoblot analysis
Immunoblot analysis was performed as described pre-
viously [7,26,27]. The primary antibodies used were
anti-VE-cadherin (R&D Systems, Wiesbaden, Germany),
anti-N-cadherin and anti-b-actin (Sigma-Aldrich,
Munich, Germany). The secondary antibodies were
horseradish peroxidase-conjugated anti-rabbit immuno-
globulin G (IgG) (Novus Biologicals, Littleton, CO,
USA), anti-goat IgG (Jackson Immunoresearch, Soham,
UK) and anti-mouse IgG (Cell Signaling Technology,
Frankfurt, Germany). Band intensity was quantified
using Quantity One analysis software (Bio-Rad, Her-
cules, CA, USA). Antibodies used for detection of
human VE-cadherin, N-cadherin and E-cadherin were
goat anti-VE-cadherin (Santa Cruz Biotechnology, Santa
Cruz, CA, USA), mouse anti-N-cadherin (BD Bios-
ciences, Bedford, MA, USA), mouse anti-E-cadherin (BD
Biosciences, Bedford, MA, USA). Membranes were incu-
bated with secondary antibody conjugated with IRDye
Infrared Dyes (IRDYE 800CW donkey anti-goat, IRDYE
800CW donkey anti-mouse), and bands were revealed
with a LI-COR scanner (LI-COR Biosciences, Lincoln,
NE, USA).
Immunofluorescence staining of cells
Cells (2 × 105) were seeded on glass coverslips. After 24 h,
cells were fixed as described [7] and stained with the
following primary antibodies: anti-VE-cadherin (R&D
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Systems, Wiesbaden, Germany), anti-N-cadherin (BD
Biosciences, Bedford, MA, USA), anti-E-cadherin (Sigma-
Aldrich, Munich, Germany), anti-b-catenin (Cell Signaling
Technology, Frankfurt, Germany) and anti-Vimentin
(Sigma-Aldrich, Munich, Germany). The secondary anti-
bodies used were goat anti-rat Alexa 594, chicken anti-
rabbit Alexa 594 and rabbit anti-goat 594 (Molecular
Probes, Leiden, The Netherlands). Antibodies used for
detection of human VE-cadherin, N-cadherin and E-cad-
herin were: goat anti-VE-cadherin (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA), mouse anti-N-cadherin (BD
Biosciences, Bedford, MA, USA), mouse anti-E-cadherin
(BD Biosciences, Bedford, MA, USA).
Tumor experiments
Ep5ExTu cells were cultured in DMEM-F12 supplemen-
ted with 15% FCS. Cells were then trypsinized, rinsed
twice in 5 ml PBS and resuspended in PBS at a concen-
tration of 1 × 106 cells/ml. Tumor experiments were per-
formed as described previously [27] with eight- to
twelve-week-old female BALB/c mice (Taconic, Ejby,
Denmark). All tumors were measured with calipers every
two to three days and the volume of each measurement
was calculated as: (width2 × length)/2. Tumors were col-
lected 10 or 15 days after injection, embedded in Tissue
Tek (Sakura Finetek, Staufen, Germany) and frozen on
dry ice. Animal experimentation was approved by the
Landesdirektion Dresden, Germany (Re: 24-9168.11-1/
2009-19).
Immunofluorescence staining of frozen tumor sections
Eight μm frozen sections were cut and air dried. Sections
were then fixed in 100% acetone for 10 min at -20°C and
air dried. Rehydrated sections were stained with antibo-
dies as described for immunofluorescence staining of
cells.
Immunohistochemistry on human tumor tissue
microarray
The tissue microarray included formalin-fixed, paraffin-
embedded probes of 84 invasive breast cancers. The clini-
copathological features are summarized in Additional file
2. Specimens were dewaxed, and immunohistochemical
staining was performed using an automated immunostai-
ner according to the manufacturer’s protocol (Bench-
mark; Ventana Medical Systems, Tucson, AZ, USA) as
described previously [7]. The primary antibodies were
anti-human VE-cadherin and anti-human N-cadherin
(Polyclonal; Abcam, Cambridge, UK). The signal was
amplified using the VENTANA amplification kit (Bench-
mark; Ventana Medical Systems, Tucson, AZ, USA) and
visualized using avidin-biotin labeling and 3, 3’-diamino-
benzidine. Slides were counterstained with hematoxylin.
Evaluation of the staining was performed separately for
nuclear, cytoplasmic and membrane-associated expres-
sion in a semi-quantitative manner. Expression was con-
sidered as positive if at least 1% of the tumor cells were
stained. Chi-squared test was used for statistical evalua-
tion of the results, and a P value < 0.05 was considered as
statistically significant. The study was approved by the
Ethics Committee (Ethikkommisssion) of the Faculty of
Medicine of the University of Dresden (Re: EK59032007).
Results
N-cadherin and VE-cadherin are co-expressed in human
breast cancer tissue
We recently reported that VE-cadherin is aberrantly
expressed in approximately 73% of human invasive mam-
mary carcinomas (27 out of 37 cases). Expression was
observed in a subset of tumor cells, as well as in the tumor
vasculature. Here, we have extended this analysis by exam-
ining a larger number (n = 84) of invasive breast cancer
specimens in a tissue microarray. This array included car-
cinomas of different tumor stages, histological types and
histopathological grades. The clinicopathological features
are summarized in Additional file 2. VE-cadherin protein
was detected by immunohistochemistry in a subset of
tumor cells in 61 of the 79 (77%) invasive carcinomas
examined (Table 1). Yet, we did not observe a significant
correlation between VE-cadherin expression and clinico-
pathological factors (data not shown). 82% of the tumors
expressed N-cadherin protein, and 62% of the specimens
were positive for both VE- and N-cadherin. This result
shows for the first time that these two cadherins can be
co-expressed in breast cancer (Figure 1). However, the
localization of VE- and N-cadherin in tumor cells appears
to be partially different (Table 1). VE-cadherin membrane
staining was observed in 31 tumors (39%) whereas N-cad-
herin was localized at the membrane in only 6 breast can-
cers (7%). Table 2 summarizes the relationship between
N-cadherin expression and the clinicopathological features
of the breast cancers: membrane localization of N-
Table 1 Neural (N)-cadherin and vascular endothelial




Positzive Negative Positive expression
percentage
Membrane 6 78 7%
Cytoplasmic 29 55 34%
Nuclei 55 29 65%
Total expression 69 15 82%
VE-cadherin
expression
Positive Negative Positive expression
percentage
Membrane 31 48 39%
Cytoplasmic 56 23 70%
Total expression 61 18 77%
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cadherin in tumors significantly correlated with smaller
tumor size (5 out of 36 cases pT1 vs. 1 out of 47 cases
pT2, P = 0.04); in contrast, nuclear expression of N-
cadherin was observed primarily in poorly differentiated
tumors.
N-cadherin knockdown results in reduction of VE-
cadherin expression in breast cancer cells
To investigate the functional role of N-cadherin in breast
cancer cells, N-cadherin expression was silenced by
transfection of two different siRNAs into Ep5ExTu cells.
Unexpectedly, downregulation of N-cadherin in Ep5ExTu
cells resulted in reduced VE-cadherin expression (see
Additional file 3). Next, we stably silenced N-cadherin
expression by lentiviral transduction with two different
short hairpin RNAs (shRNAs), Sh-Ncad1 and Sh-Ncad2.
We selected three independent cell clones (Sh-Ncad1.1,
Sh-Ncad1.2 and Sh-Ncad2) that displayed reduced
N-cadherin expression in comparison to the control cell
line that had been transduced with a scrambled shRNA
(Sh-Scr) (Figure 2a). In Sh-Ncad1.1 and Sh-Ncad2 cells,
N-cadherin protein levels were reduced by approximately
75% as compared to the Sh-Scr cell line, whereas in Sh-
Ncad1.2 cells, N-cadherin protein expression was
reduced by only 45%. Consistent with the results
obtained from the transient transfection with siRNA (see
Additional file 3), immunoblot analysis (Figure 2a) and
immunofluorescence staining (see Additional file 3) of
the cells revealed also a clear reduction in VE-cadherin
expression in the N-cadherin knockdown cell lines
(Sh-Ncad1.1, Sh-Ncad1.2 and Sh-Ncad2). This result sug-
gests that N-cadherin is required for sustaining the
expression of VE-cadherin in Ep5ExTu cells.
In contrast, VE-cadherin silencing by lentiviral transduc-
tion of Ep5ExTu cells with shRNA specific for VE-cad-
herin affected the protein level of N-cadherin only
slightly because N-cadherin levels were similar to the Sh-
VE-cadherin cell lines (Sh-VEcad1 and Sh-VEcad2) and
the control Sh-Scr cell line (Figure 2b). However, as
described for endothelial cells [28,29], VE-cadherin
expression affected N-cadherin localization (Figure 2c
and [7]). In the Sh-Scr cell line, VE-cadherin was
expressed heterogeneously and presented at the cell sur-
face similar to untransfected Ep5ExTu cells, whereas N-
cadherin staining was uniformly distributed over the
cell and localized at cell-cell contacts in only a few cells
(Figure 2c). In cells silenced for VE-cadherin (Sh-VEcad1),
N-cadherin was enriched at cell-cell contacts. This shows
that silencing of VE-cadherin leads to a redistribution of
a b
Figure 1 Immunohistochemical staining of vascular endothelial (VE)-cadherin (a) and neural (N)-cadherin (b) in human breast cancer
tissue.
Table 2 Correlation between neural (N)-cadherin
expression and clinicopathological factors.
N-cadherin membrane expression
Parameter Negative Positive P value
Tumor size (pT) 0.040
1 (Tumor size ≤ 2 cm) 31 5
2 (Tumor size > 2 cm) 46 1
N-cadherin nuclear expression
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N-cadherin to cell-cell contacts, without influencing its
expression levels significantly.
We also investigated the expression of VE-cadherin and
N-cadherin in the human breast carcinoma cell line, SUM
149. By western blot analysis, immunofluorescence stain-
ing and qRT-PCR, SUM 149 cells expressed VE-cadherin
and N-cadherin, in addition to E-cadherin (see Additional
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Figure 2 Neural (N)-cadherin regulates vascular endothelial (VE)-cadherin expression in Ep5ExTu cells. (a) N-cadherin silencing in
Ep5ExTu cells transduced either with a scrambled shRNA-containing virus (Sh-Scr) or with Sh-N-cadherin virus (Sh-N-cad1.1, Sh-N-cad1.2 and Sh-
N-cad2). The bars represent the relative N-cadherin or VE-cadherin protein levels in Sh-N-cadherin cell lines versus the Sh-Scr cell line, as
determined by western blot analysis. (b) VE-cadherin protein expression was examined by western blot in Ep5ExTu cells that were transduced
with the VE-cadherin shRNA (Sh-VE-cad-1 and Sh-VE-cad-2) and in the Sh-Scr cell lines. b-actin was detected as loading control. (c)
Immunofluorescence staining for VE-cadherin or N-cadherin in Sh-VE-cad-1 and Sh-Scr cells. Ep5ExTu cells were used as a positive control for the
localization of VE-cadherin and N-cadherin. Nuclear staining with DAPI is also shown. Bar, 60 μm.
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VE-cadherin mRNA levels but not vice versa. Thus, regu-
lation of VE-cadherin by N-cadherin is observed in both
mouse and human breast cancer cells.
Suppression of N-cadherin in mesenchymal Ep5ExTu cells
induces MET and re-expression of E-cadherin
Ep5ExTu cells exhibit fibroblastoid characteristics, such
as elongated shape and relatively weak cell-cell contacts
as compared to epithelial cells [7,25,26]. We have pre-
viously observed that E-cadherin is expressed in epithelial
Ep5 cells, but not in fibroblastoid Ep5ExTu cells, in
agreement with the observation that E-cadherin is
downregulated during EMT [7]. The two Ep5ExTu cell
lines in which N-cadherin expression was efficiently
silenced by shRNA (Sh-Ncad1.1 and Sh-Ncad2), dis-
played a cobblestone-like appearance characteristic for
epithelial cells, with individual cells abutting each other
(Figure 3a). Consistent with the idea that these cells have
undergone MET, the epithelial phenotype of these Sh-N-
cadherin cell lines was associated with re-expression of
E-cadherin (Figure 3b and 3c). Thus, E-cadherin can be
re-induced in Ep5ExTu cells by blocking N-cadherin
expression. Interestingly, E-cadherin expression was
stronger in the Sh-Ncad1.1 and Sh-Ncad2 cell lines than
Figure 3 Neural (N)-cadherin silencing in Ep5ExTu cells induced epithelial (E)-cadherin expression and influenced its localization in the
cells in a dose-dependent manner. (a) Phase contrast microscopy of control cell lines (Sh-Scr) and Sh-N-cadherin cell lines (Sh-N-cad1.1,
Sh-N-cad1.2 and Sh-N-cad2). Bar, 100 μm. (b) E-cadherin mRNA levels in Ep5ExTu clones. (c) The graph represents the quantification of the relative
amount of E-cadherin mRNA in three independent experiments. b-actin was used as loading control. The mean ± SD is indicated. (n = 3)
(**, P < 0.0012 and ***, P < 0.0009). (d) Immunolocalization of E-cadherin in Ep5 (Bar, 30 μm) and Ep5ExTu (Bar, 60 μm) clones by immunofluorescence
microscopy. Nuclear staining with DAPI is also shown.
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in the Sh-Ncad1.2 cell line (Figure 3b and 3c), in which
N-cadherin expression is only moderately suppressed.
Similar to Ep5 cells, E-cadherin staining was observed at
sites of cell-cell contacts in both Sh-Ncad1.1 and Sh-
Ncad2 cell lines (Figure 3d). These results suggest that
the re-induction of E-cadherin in Ep5ExTu cells and its
localization at cell-cell contacts correlates with the extent
of N-cadherin reduction: the lower the N-cadherin levels
are, the more pronounced is the epithelial phenotype.
Silencing VE-cadherin in Ep5ExTu cells, in contrast, led
to only a partial gain of the epithelial morphology and
was not associated with re-induction of E-cadherin (see
Additional file 5). This shows that N-cadherin has a
more pronounced influence on the maintenance of the
mesenchymal tumor cell phenotype than VE-cadherin.
N-cadherin silencing influences b-catenin localization and
the expression of EMT regulator genes in Ep5ExTu cells
b-catenin accumulation in the nuclei of carcinoma cells
and transcriptional activation of its target genes are
known to take place during malignant transformation,
thereby stimulating tumor progression [2,30-33]. E-cad-
herin can sequester b-catenin in epithelial cells, thus low-
ering the amount of cytoplasmic and nuclear b-catenin,
decreasing its transcriptional activity and inhibiting its
tumorigenic potential [34]. To investigate whether
the localization of b-catenin in Ep5ExTu breast cancer
cells is altered by N-cadherin silencing, we performed
immunofluorescence staining. In (epithelial) Ep5 cells, b-
catenin was localized at the plasma membrane (Figure 4a)




















































































































Figure 4 Significant suppression of neural (N)-cadherin in Ep5ExTu cells influences b-catenin localization and the level of epithelial-
mesenchymal transition (EMT) regulator genes in Ep5ExTu cells. (a) Immunolocalization of b-catenin in the Sh-Scr cell line and Sh-N-
cadherin cell lines (Sh-N-cad1.1, Sh-N-cad1.2 and Sh-N-cad2). Ep5 cells were used as a positive control for the localization of b-catenin in
epithelial cell lines that have not undergone EMT. Bar, 30 μm. (b) and (c) mRNA level of Snail, vimentin and Smad interacting protein 1 (SIP1) in
Ep5ExTu clones. (d), (e) and (f) the bars indicate the relative expression levels of snail, vimentin and SIP1 mRNA in three independent
experiments. b-actin was used as loading control. The mean ± SD is (*, P < 0.0491 and **, P < 0.0014) (n = 3).
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b-catenin was localized at the plasma membrane along
with E-cadherin in the two Sh-N-cadherin cell lines
that had greatly reduced N-cadherin (Sh-Ncad1.1 and
Sh-Ncad2) (Figure 3d, Figure 4a). In contrast, clone Sh-
Ncad1.2, which had moderately reduced N-cadherin, and
clone Sh-VE-cadherin showed no significant differences in
b-catenin localization compared to the Sh-Scr control cell
line (Figure 4a and Additional file 6), and we observed
localization of b-catenin to cell-cell contacts in only a few
cells. Together, these results show that efficient silencing
of N-cadherin in mesenchymal murine mammary carci-
noma cells leads to the re-expression of E-cadherin and
the co-localization of this receptor with b-catenin at the
plasma membrane.
Nuclear localization of b-catenin and the expression of
vimentin are involved in epithelial-to-mesenchymal transi-
tion and correlate with enhanced invasive and migratory
properties of cells [24,35]. Because b-catenin can stimulate
vimentin expression [36], we tested whether the recruit-
ment of b-catenin to the cell membrane of the N-cadherin
knockdown cell lines is correlated with changes in the
expression of EMT-related genes. The expression of the
transcription factor Snail was reduced in all Sh-N-cadherin
cell lines as compared to the control cell line (Figure 4b
and 4d), whereas the expression of Smad interacting pro-
tein-1 (SIP1) and vimentin, which are involved in EMT
[37], was downregulated only in Sh-Ncad1.1 and Sh-
Ncad2 cell lines (Figure 4c-f and Additional file 6).
Whether or not vimentin and SIP1 expression is regulated
by N-cadherin remains to be determined.
Efficient silencing of N-cadherin in Ep5ExTu cells inhibits
tumor growth in vivo without affecting cell proliferation
in vitro
We have previously shown that silencing VE-cadherin
leads to reduced Ep5ExTu cell proliferation and tumor
growth [7]. To determine if N-cadherin downregulation
has a similar effect, we evaluated the proliferation of Sh-
N-cadherin cell lines in vitro by BrdU staining. Sh-VEcad2
and Sh-Ncad1.2 cells displayed lower proliferation rates
than the control cell line, whereas the proliferation rate
of Sh-Ncad1.1 and Sh-Ncad2 cells was not reduced
(Figure 5a). To study the effect of N-cadherin on tumor
growth, each of the three Sh-N-cadherin cell lines and the
control cell line (Sh-Scr) were injected subcutaneously
into BALB/c mice. All Sh-N-cadherin cell lines grew sig-
nificantly slower than the control cell line (Figure 5b).
Notably, the Sh-Ncad1.1 and Sh-Ncad2 cell lines, which
showed the strongest reduction of N-cadherin expression,
hardly grew in vivo. The Sh-Ncad1.2 cell line showed an
intermediate growth rate, similar to the Sh-VE-cadherin
cell line (Figure 5c). These data show that a strong
(approximately 75%) reduction of N-cadherin expression
in Ep5ExTu cells is necessary to inhibit tumor growth
efficiently. To perform a histological analysis of tumor
tissue, we isolated tumors at day 10 post injection. Down-
regulation of N-cadherin and VE-cadherin expression in
the Sh-Ncad1.2 and Sh-Ncad2 tumors was confirmed by
immunofluorescence staining (see Additional file 7). E-
cadherin staining was only visible in the Sh-N-cadherin
tumors (Figure 5d), and was more intense in Sh-Ncad2
than in Sh-Ncad1.2 tumors. Because vimentin expression
has been implicated in carcinogenesis [38,39], we also
examined the expression of this intermediate filament in
the different experimental tumor groups. Vimentin
expression was strongly reduced only in the Sh-Ncad2 cell
line (Figure 5d). Taken together, our results suggest that
both re-induction of E-cadherin expression and downre-
gulation of vimentin expression contribute to tumor
growth inhibition resulting from N-cadherin silencing in
Ep5ExTu cells.
Forced expression of VE-cadherin in N-cadherin deficient
tumor cells does not enhance cell proliferation in vitro or
tumor growth
Because N-cadherin silencing in Ep5ExTu cells also led to
a reduction of VE-cadherin expression, and VE-cadherin
silencing inhibited tumor growth, we wanted to determine
whether the loss of VE-cadherin contributes to the tumor
growth inhibition resulting from silencing N-cadherin. To
address this question, we determined whether the forced
expression of VE-cadherin in Sh-Ncad2 cells can affect
tumor growth of N-cadherin-deficient cancer cells. A len-
tiviral expression vector encoding VE-cadherin was there-
fore introduced into Sh-Ncad2 cells. Two independent
clones (N-cadVE1 and N-cadVE2) showed VE-cadherin
expression levels similar to that of the Sh-Scr cell line
(Figure 6a). The forced expression of VE-cadherin had no
influence on cell morphology (see Additional file 8), and
the expression of N-cadherin and vimentin in N-cadVE1
and N-cadVE2 cells remained unchanged (Figure 6b).
These results suggest that expression of VE-cadherin in
the absence of N-cadherin cannot induce Sh-Ncad2 cells
to undergo EMT.
Next, we explored whether forced expression of VE-
cadherin can influence cell proliferation. No significant
difference in cell proliferation was observed between the
VE-cadherin-expressing cell lines (N-cadVE1 and N-
cadVE2) and control cell line (Sh-Ncad2) (see Additional
file 8). To evaluate whether forced VE-cadherin expression
influences the growth of Sh-N-cad2 tumors, we inoculated
cells from the VE-cadherin-expressing lines (N-cadVE1
and N-cadVE2), Sh-N-cad2 or control Sh-Scr cell lines
into wild-type BALB/c mice and monitored tumor growth.
The VE-cadherin-expressing cell lines (N-cadVE1 and N-
cadVE2) and Sh-Ncad2 displayed comparable growth rates
and scarcely grew in vivo (Figure 6c). These results show
that forced VE-cadherin expression cannot accelerate
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tumor growth in the absence of N-cadherin expression,
indicating that the concomitant loss of VE-cadherin
expression does not contribute to the reduction of tumor
growth resulting from N-cadherin silencing.
Forced VE-cadherin expression in Ep5ExTu cells does not
affect E-cadherin localization
Since the localization of VE-cadherin within adherens junc-
tions is required for its function [5], we examined the pos-
sibility that the inappropriate localization of VE-cadherin is
responsible for its inability to restore tumor growth of N-
cadherin-deficient cells. By immunofluorescence staining,
VE-cadherin expression was observed at the cell borders in
N-cadVE1 cells, similar to control Sh-Scr cells (Figure 7).
E-cadherin was also localized at cell-cell junctions as in the
Sh-Ncad2 control cell line (Figure 7). This shows that VE-
cadherin cannot displace E-cadherin from the cancer cell
surface.
Discussion
Breast cancer is one the leading causes of death due to can-
cer worldwide. Although the genetic defects underlying
breast carcinogenesis have been extensively studied, impor-
tant signaling pathways involved in the progression of this
specific tumor type are still poorly characterized. The loss
of E-cadherin and concomitant gain of N-cadherin expres-
sion is known to promote EMT and carcinoma progression.
Our previous observation that endothelial cell-selective VE-
cadherin is expressed aberrantly in breast cancer cells and
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Figure 5 The efficient suppression of neural (N)-cadherin in Ep5ExTu cells inhibits tumor growth in vivo without affecting cell
proliferation in vitro. (a) Twenty-four hours after seeding equal numbers of cells, cell proliferation was quantified by measuring
bromodeoxyuridine (BrdU) incorporation. The mean ± SD is (**, P < 0.0010) (n = 12). (b) Sh-N-cadherin cell lines (Sh-N-cad1.1, Sh-N-cad1.2 and
Sh-N-cad2) or Sh-Scr were injected subcutaneously into BALB/c mice. (**, P < 0.0075 and ***, P < 0.0001) (n = 10). (c) Sh-N-cadherin cell lines
(Sh-N-cad1.2 and Sh-N-cad2), Sh-VE-cadherin cell line (Sh-VE-cad-2) or Sh-Scr cell line injected into BALB/c mice. The mean ± SD is indicated (*, P
< 0.334; **, P < 0.0083; ***, P < 0.0001) (n = 8). (d) Immunofluorescence staining for epithelial (E)-cadherin and vimentin on tumor sections.
Nuclear staining with DAPI is also shown. Bar, 100 μm.
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us to analyze the specific roles of these cadherins as well as
their interplay in experimental breast cancer in more detail.
Here, we show that N-cadherin silencing in murine breast
cancer cells suppresses tumor growth by upregulating E-
cadherin, repressing EMT regulators, and reversing the
invasive mesenchymal phenotype to epithelial phenotype.
Although both N-cadherin and VE-cadherin promote
tumor growth, their influence on E-cadherin expression in
mesenchymal tumor cells is divergent: whereas N-cadherin
is capable of repressing E-cadherin expression in Ep5ExTu
cells, VE-cadherin has no effect on its expression levels [7].
Moreover, N-cadherin is required for maintaining VE-cad-
herin expression, but not vice versa. The regulation of VE-
cadherin expression by N-cadherin is a novel mechanism
of tumor progression in breast cancer and shows that N-
cadherin both inhibits the expression of E-cadherin and
stimulates the expression of VE-cadherin.
The downregulation of VE-cadherin in the N-cadherin-
deficient Ep5ExTu cells shows that N-cadherin is required
(although not necessarily sufficient) for VE-cadherin
expression in aggressive carcinoma cells. Regulation of
VE-cadherin by N-cadherin was already described before
in (nonmalignant) human umbilical vein endothelial cells
(HUVEC) [40], however, evidence for direct regulation of
VE-cadherin by N-cadherin is lacking, and the precise
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Figure 6 Forced expression of vascular endothelial (VE)-cadherin in Sh-N-cad18-4 cell line does not accelerate tumor growth in vivo.
(a) Western blot analysis for VE-cadherin in Sh-N-cadherin (Sh-N-cad2), Sh-N-cad2-expressing VE-cadherin cell lines (N-cadVE-1 and N-cadVE-2),
and Sh-Scr. (b) Vimentin and neural (N)-cadherin mRNA expression levels in Ep5ExTu clones. Diagrams in (c) and (d) depict the quantification of
the relative amount of vimentin and N-cadherin mRNA as determined in three independent experiments. b-actin was used as loading control.
(e) Sh-N-cadherin (Sh-N-cad2), Sh-N-cad2-expressing VE-cadherin cell lines (N-cadVE-1 and N-cadVE-2) or Sh-Scr cell lines were injected into
BALB/c mice. The mean ± SD is given (***, P < 0.0001) (n = 12).
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determined. The ability of N-cadherin to regulate VE-cad-
herin was nonreciprocal because VE-cadherin silencing
had no effect on N-cadherin expression. However, as
described also for other cell types [28,29], VE-cadherin
expression in Ep5ExTu cells affected the localization of N-
cadherin protein. In control Ep5ExTu cells, which express
both cadherins, N-cadherin displayed a nonjunctional dis-
tribution whereas in Sh-VE-cadherin knockdown cell
lines, N-cadherin was enriched at cell-cell junctions.
Whether VE-cadherin expression can influence signaling
pathways regulated by N-cadherin as a consequence of
excluding it from cell contacts remains to be determined.
There is growing evidence indicating that EMT is a
reversible process in cancer cells. Recently, it was hypothe-
sized that tumor cells in metastatic sites can undergo re-
differentiation and undergo MET [1,3,6]. This transition
could allow metastatic cells to adapt to a new microenvir-
onment. Re-expression of E-cadherin is a critical compo-
nent of the MET [41,42]. However, little is known about
the exact mechanism and biological or clinical significance
of MET in cancer. Islam et al. reported that blocking N-
cadherin expression upregulates E-cadherin expression in
squamous epithelial cells [10]. Interestingly, we observed
that N-cadherin silencing promoted multiple aspects of
MET in Ep5ExTu cells in a concentration-dependent man-
ner, including morphological changes, increased levels of
E-cadherin and decreased levels of mesenchymal markers.
In contrast, VE-cadherin silencing led only to a weaker
induction of epithelial markers and had no effect on E-
cadherin expression, indicating that MET is activated more
efficiently by N-cadherin silencing than by VE-cadherin
silencing. This difference might be explained by the differ-
ence in b-catenin localization in Sh-N-cadherin and Sh-
VE-cadherin cell lines. Interestingly, in Sh-N-cadherin cell
lines (Sh-Ncad1.1 and Sh-Ncad2) that displayed the most
efficient N-cadherin downregulation, b-catenin was loca-
lized at the cell membrane like in the epithelial Ep5 cell
line. As reported by other groups, alteration of b-catenin
localization alone can be sufficient for the suppression of
an invasive phenotype [24,43].
The intermediate filament vimentin is an important
marker of EMT and its expression is related to the adhe-
sion and migration properties of tumor cells [44]. A pre-
vious study using human breast cancer cells showed that
accumulation of cytoplasmic or nuclear b-catenin and
vimentin expression coincide [36]. Additionally, b-catenin
can directly transactivate vimentin expression through its
binding to the T cell factor (TCF)/lymphoid enhancer
Figure 7 Vascular endothelial (VE)-cadherin expression in Sh-N-cad2 has no influence on epithelial (E)-cadherin localization.
Immunofluorescence staining for E-cadherin and VE-cadherin in the Sh-N-cadherin cell line (Sh-N-cad2) and in Sh-N-cad2 cell lines expressing
VE-cadherin (N-cadVE-1). Ep5ExTu cells were used as positive control for VE-cadherin and neural (N)-cadherin localization. Nuclear staining with
DAPI is also shown. Bar, 30 μm.
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factor (LEF) 1 transcription factor family. Vimentin
expression was consistently downregulated in mammary
carcinoma cell lines in which b-catenin was localized at
the plasma membrane (Sh-Ncad1.1 and Sh-Ncad2), but
vimentin levels remained unchanged in lines that that
showed cytoplasmic and/or nuclear distribution of b-cate-
nin (Sh-Ncad1.2 and Sh-VEcad1).
Several transcriptional regulators are known to repress
E-cadherin expression and thereby induce EMT. Among
these, we analyzed the expression level of Snail and SIP1,
which emerged as key factors regulating E-cadherin
expression [45]. Whereas the level of Snail was downre-
gulated in all Sh-N-cadherin cell lines, the level of SIP1
was decreased only in the Sh-Ncad1.1 and Sh-Ncad2 cell
lines, which expressed higher E-cadherin levels. This
result therefore suggests that the re-expression of E-cad-
herin is stimulated more efficiently if the expression of
both transcriptional repressors of E-cadherin is
decreased.
Deregulation of E-cadherin in breast cancer correlates
with higher tumor grade and metastatic tumor cell beha-
vior [46,47]. Also in other cell types and in animal models,
E-cadherin has been shown to act as a suppressor of
tumor growth and invasion [48]. In our study, suppressing
N-cadherin significantly reduced Ep5ExTu tumor growth.
Remarkably, Sh-Ncad1.1 and Sh-Ncad2 cell lines hardly
grew in vivo, and mice injected with either cell line were
often tumor-free 14 days after inoculation. Histological
analysis of tumor sections isolated at day 10 post injection
confirmed the re-expression of E-cadherin and downregu-
lation of vimentin in Sh-Ncad2 tumors in vivo. Since N-
cadherin silencing did not change the proliferation rate of
Sh-Ncad1.1 and Sh-Ncad2 in vitro, it is likely that the phe-
notypic reversion of these cell lines, along with E-cadherin
expression and associated b-catenin, leads to the inhibition
of tumor growth in vivo. In contrast, moderate suppres-
sion of N-cadherin in Sh-Ncad1.2, which greatly inhibits
VE-cadherin expression, resulted in a growth rate similar
to the Sh-VEcad2 cell line. This growth inhibition corre-
lates well with the decrease in cell proliferation observed
for both cell lines in vitro. It is therefore possible that the
growth inhibition of the Sh-Ncad1.2 cell line is caused pri-
marily by the strong VE-cadherin suppression.
Does the introduction of VE-cadherin in N-cadherin
(and consequently VE-cadherin) deficient cells restore
tumor growth? The forced expression of VE-cadherin in
the Sh-Ncad2 cells (that had undergone MET) did not
change their epithelial phenotype, as indicated by
unchanged E-cadherin and vimentin expression levels.
Additionally, junctional localization of E-cadherin was pre-
served in VE-cadherin re-expressing cell lines. In line with
the unaltered epithelial phenotype, forced expression of
VE-cadherin failed to evoke a significant difference in
tumor growth; the VE-cadherin-expressing and control
cells had similar growth rates in vivo. These results suggest
that VE-cadherin expression, at least in the presence of
E-cadherin, is not sufficient to promote tumor progres-
sion.
Conclusions
Our study shows for the first time that N-cadherin and
VE-cadherin are co-expressed in human breast cancer. N-
cadherin controls the expression of VE-cadherin in aggres-
sive mouse breast cancer cells and has an important role
in maintaining the mesenchymal phenotype and promot-
ing tumor progression. VE-cadherin, on the other hand,
regulates the subcellular localization of N-cadherin by dis-
placing it from the cell surface. Our study supports the
hypothesis that the interplay between cadherins in breast
cancer progression is not limited to the classical ‘cadherin
switch’, which involves the loss of E-cadherin expression
or function and the gain of N-cadherin, but comprises
also an intricate interdependence of N-cadherin and VE-
cadherin.
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